key: cord-0712945-t5g6x1xx
authors: Li, Ruofan; Mor, Michael; Ma, Bingting; Clark, Alex E.; Alter, Joel; Werbner, Michal; Lee, Jamie Casey; Leibel, Sandra L.; Carlin, Aaron F.; Dessau, Moshe; Gal-Tanamy, Meital; Croker, Ben A.; Xiang, Ye; Freund, Natalia T.
title: Conformational Flexibility in Neutralization of SARS-CoV-2 by Naturally Elicited Anti-SARS-CoV-2 Antibodies
date: 2022-04-03
journal: bioRxiv
DOI: 10.1101/2022.04.03.486854
sha: a9f3b8e2ffd6818d1e9a93994f95bbf7a1331bc0
doc_id: 712945
cord_uid: t5g6x1xx

As new variants of SARS-CoV-2 continue to emerge, it is important to assess the neutralizing capabilities of naturally elicited antibodies against SARS-CoV-2. In the present study, we evaluated the activity of nine anti-SARS-CoV-2 monoclonal antibodies (mAbs), previously isolated from convalescent donors infected with the Wuhan-Hu-1 strain, against the SARS-CoV-2 variants of concern (VOC) Alpha, Beta, Gamma, Delta and Omicron. By testing an array of mutated spike receptor binding domain (RBD) proteins, cell-expressed spike proteins from VOCs, and neutralization of SARS-CoV-2 VOCs as pseudoviuses, or as the authentic viruses in culture, we show that mAbs directed against the ACE2 binding site (ACE2bs) are far more sensitive to viral evolution compared to anti-RBD non-ACE2bs mAbs, two of which kept their potency against all VOCs tested. At the second part of our study, we reveal the neutralization mechanisms at high molecular resolution of two anti-SARS-CoV-2 neutralizing mAbs by structural characterization. We solved the structures of the Delta-neutralizing ACE2bs mAb TAU-2303 with the SARS-CoV-2 spike trimer and RBD at 4.5 Å and 2.42 Å, respectively, revealing a similar mode of binding to that between the RBD and the ACE2 receptor. Furthermore, we provide five additional structures (at resolutions of 5.54 Å, 7.76 Å, 6.47 Å, 3.45 Å, and 7.32 Å) of a second antibody, non-ACE2bs mAb TAU-2212, complexed with the SARS-CoV-2 spike trimer. TAU-2212 binds an exclusively quaternary epitope, and exhibits a unique, flexible mode of neutralization that involves transitioning between five different conformations, with both arms of the antibody recruited for cross linking intra- and inter-spike RBD subunits. Our study provides new mechanistic insights about how antibodies neutralize SARS-CoV-2 and its emerging variants and provides insight about the likelihood of reinfections.

Within two years of the emergence of SARS Coronavirus 2 (SARS-CoV-2) in Wuhan 46 province, the original virus strain has been completely replaced by more transmissible 47 variants, with Omicron emerging as the latest variant of concern (VOC). In view of the 48 unexpectedly fast rates of viral evolution, it is important to estimate the degree to which 49 neutralizing antibodies elicited naturally following infection with the original wild type strain 50 (Wuhan-Hu-1), are cross reactive with circulating, present and future, VOCs. This is 51 particularly relevant considering recent reports that vaccination provides considerably less 52 protection against SARS-CoV-2 variants than against the original strain 1-3 .

The SARS-CoV-2 antibody response has been profiled at the sequence, structural, separately had no effect ( Fig. 1c-d, Extended Data Fig. 1) . Overall, we conclude that ACE2bs 121 mAbs are more sensitive to mutations in the RBDs than non-ACE2bs mAbs.

Mutations outside the RBD may also affect the activity of RBD-binding mAbs by 123 altering the conformational organization of the trimer 29 . Therefore, we next expressed the full-124 length spike protein of wild type, Alpha, Beta, and Delta variants (Extended Data Table S1) 125 on Expi293F cells, and assayed the ability of each mAb to inhibit binding of soluble human 126 ACE2 (hACE2) by flow cytometry. The Gamma full-length spike protein was not produced 127 since the RBD of this variant exhibited similar activity to the Beta RBD. As expected, most of 128 the ACE2bs mAbs effectively inhibited the ACE2:spikewild type and ACE2:spikeAlpha interactions, 129 but not those between the ACE2:spikeBeta and ACE2:spikeDelta. The mAb TAU-2212, which can 130 be tested in this assay, demonstrated 25-40% ACE2:spike inhibition when tested against the 131 wild type, Alpha and Delta strains, but had no activity against Beta ( Fig. 2a 

We next evaluated the ability of the mAbs to prevent infection. We employed a 140 pseudoviral neutralization assay and an authentic SARS-CoV-2 infection in Vero-TMPRSS2 141 cells assay to test the activity of the nine mAbs against SARS-CoV-2 wild type and VOCs ( Fig.   142 3). In accordance with the ELISA and flow cytometry results, the Alpha VOC behaved similarly 143 to the wild type strain, while the Beta and Omicron variants were the most resistant, followed 144 by Gamma and Delta. In agreement with the ELISA and flow cytometry results, mAb TAU-145 2303 was the only ACE2bs mAb that was able to neutralize Delta VOC, with improved potency 146 compared to the wild type strain (Fig. 3a) . The non-ACE2bs mAbs TAU-1109 and -2310 147 retained their efficacy against all tested VOCs, while TAU-2310 exhibited an improved activity 148 against Delta variant compared to the wild type ( Fig. 3a and b) . These results indicate a crucial 149 support role for non-ACE2bs mAbs in the presence of viral mutations that prevent 155 Viral evolution appears to be primarily focused on the ACE2bs supersite, consistent 156 with the overall superoir potency of receptor blocking mAbs to inhibit SARS-CoV-2. We 157 decided to focus on mAb TAU-2303, which is the only ACE2bs mAb that is active against the 158 Delta VOC, and mAb TAU-2212 that blocks receptor binding through recognition of a 159 conformational surface, and further investigate the structural basis of these two mAbs. To with the ecto SARS-CoV-2 spike trimer, at a resolution of 4.5 Å (Fig. 4a) . The cryoEM structure 163 revealed that one Fab2303 molecule binds one spike trimer on the protruding "up" facing RBD.

Therefore, mAb TAU-2303 can be categorized as a CoV21 30 -type mAb, that belongs to Class 165 1 RBD binding mAbs, and binds only one RBD subunit amongst the three available subunits 166 of the trimer (Fig. 4a) . We also crystallized Fab2303 in complex with SARS-CoV-2 RBD and 167 analyzed the structure at a resolution of 2.42 Å (Fig. 4b , and Extended Data Table S2 ). The 

This agrees with the crystal structure findings that residues K417 and N501 are both in direct 

thus decreasing the total binding energy calculated with PISA 33 from -9.7 kJ/mol to -9.9 kJ/mol.

In contrast, replacing lysine in position 417 by asparagine, increases the length of the 199 hydrogen bonds between the side chain polar atoms ND2H or OD1 with Fab2303-HC-Y33 200 and Fab2303-HC-Y52, which decreases the favorability of the interaction, as indicated by the 201 increase of the calculated binding energy from -9.7 kJ/mol to -9.5 kJ/mol (Fig. 4d) . The Table 4 ). In all five conformations, only the Fab portion of mAb TAU-2212 250 is visible, while the highly flexible Fc region is not seen in the reconstructed maps.

Conformations 1, 3 and 4 are composed of two, three and three bound Fabs, respectively, 252 with all the RBDs in the "down" position. In contrast, conformation 2 has one Fab per trimer, 253 with one RBD in the "up" configuration, while the other RBDs that bind the Fab appear in the 254 "down" configuration. Conformation 5 has two head-to-head spike proteins, which are 255 crosslinked by three mAbs (Fig. 5b-c) .

We determined the structures of all five conformations to resolutions of 5.54 Å, 7.76 Å, 258 6.47 Å, 3.45 Å and 9.36 Å (7.32 Å for the split single spike with three Fabs), respectively ( 

The length of the hydrogen bond between the OE2 group of E484RBD1 and the OH group of 

We used our previously reported wild type plasmid 9 as template for PCR mutagenesis 

The Fab portion of TAU-2212 was concentrated to 7 mg/mL for crystallization. The 

The structure of RBD-Fab2303 was refined by using PHENIX 53 . Data processing showed that 555 the crystal of Fab2212 belongs to the space group P6 5 . However, the merohedral twinning 556 appears to assign the crystal to the space group P6522. The structure of Fab2212 was refined 557 against the twinned data by using Refmac5 54 with the twinning operator k, h, -l and an 

Multiple SARS-CoV-2 variants escape neutralization by 646 vaccine-induced humoral immunity

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced 649 immunity

Neutralization of SARS-CoV-2 variants by convalescent and 651 BNT162b2 vaccinated serum

Potent neutralizing antibodies from COVID-19 patients define 654 multiple targets of vulnerability

Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-657 Neutralizing Antibodies from COVID-19 Patients

Convergent antibody responses to SARS-CoV-2 in convalescent 660 individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and 662 protection from disease in a small animal model

Broad neutralization of SARS-related viruses by human monoclonal 665 antibodies

Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from 667 severe COVID-19 convalescent donors

Studies in humanized mice and convalescent humans yield a SARS-670

CoV-2 antibody cocktail

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 673 mutational escape seen with individual antibodies

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-676

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant 678 strains

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing 682 antibodies

The monoclonal antibody combination REGEN-COV protects against 684 SARS-CoV-2 mutational escape in preclinical and human studies

Preliminary genomic characterisation of an emergent SARS-CoV-2 687 lineage in the UK defined by a novel set of spike mutations

Detection of a SARS-CoV-2 variant of concern in South Africa

Genomic characterisation of an emergent SARS-CoV-2 lineage in 693 Manaus: preliminary findings

SARS-CoV-2 B.1.617.2 Delta variant replication and immune 696 evasion

Infection and Vaccine-Induced Neutralizing-Antibody Responses to 698 the SARS-CoV-2 B.1.617 Variants

Omicron: a mysterious variant of 701 concern

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-703 2 variant

Escape from neutralizing antibodies by SARS-CoV-2 spike protein 705 variants

Circulating SARS-CoV-2 spike N439K variants maintain fitness 707 while evading antibody-mediated immunity

Working paper on SARS-CoV-2 spike mutations arising in Danish mink, 710 their spread to humans and neutralization data

Detection of new SARS-CoV-2 Variants Related to Mink

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and 716

The SARS-CoV-2 Spike variant D614G favors an open 718 conformational state

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal 720 Common Epitopes and Recurrent Features of Antibodies

B cell genomics behind cross-neutralization of SARS-CoV-2 variants 723 and SARS-CoV

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers 725 potency, breadth, and resilience to viral escape mutations

CCP4i2: the new graphical user interface to the CCP4 program suite

Mapping mutations to the SARS-CoV-2 RBD that escape binding 730 by different classes of antibodies

Signatures in SARS-CoV-2 spike protein conferring escape to 733 neutralizing antibodies

Ultrapotent antibodies against diverse and highly transmissible SARS-736

CoV-2 variants

The biological and clinical significance of emerging SARS-CoV-2 741 variants

Novel SARS-CoV-2 variants: the pandemics within the pandemic

Omicron SARS-CoV-2 variant: a new chapter in the COVID-745 19 pandemic

Resistance of SARS-CoV-2 variants to neutralization by monoclonal 747 and serum-derived polyclonal antibodies

Complete map of SARS-CoV-2 750 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with 751 LY-CoV016

SARS-CoV-2 RBD antibodies that maximize breadth and resistance to 754 escape

Ultrapotent human antibodies protect against SARS-CoV-2 756 challenge via multiple mechanisms

SARS-CoV-2 neutralizing antibody structures inform therapeutic 759 strategies

On the Calculation of TCID50 for Quantitation of Virus 761 Infectivity

Virology: A Laboratory Manual

A simple method of estimating fifty per cent endpoints

Cryo-EM structure of the 2019-nCoV spike in the prefusion 767 conformation

Processing of X-ray diffraction data collected in oscillation 769 mode

Phaser crystallographic software

Coot: model-building tools for molecular graphics

PHENIX: a comprehensive Python-based system for 776 macromolecular structure solution

REFMAC5 for the refinement of macromolecular crystal 779 structures

The CCP4 suite: programs for protein 782 crystallography

UCSF Chimera--a visualization system for exploratory research 785 and analysis

UCSF ChimeraX: Meeting modern challenges in visualization and 787 analysis

MotionCor2: anisotropic correction of beam-induced motion for 789 improved cryo-electron microscopy

Real-time CTF determination and correction

New tools for automated high-resolution cryo-EM structure 794 determination in RELION-3

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike 796

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-798 2 spike

Fourier shell correlation threshold criteria

Prevention of overfitting in cryo-EM structure 802 determination

Predominant autoantibody production by early human B cell 804 precursors

Quantifying the local resolution of cryo-806 EM density maps

Crystal structure of a neutralizing human IGG against HIV-1: a 808 template for vaccine design

hACE2-APC positive cells in the presence of each mAb, dividing it by the percent of

APC positive cells (hACE2 only), and normalizing to 100%. c, Pie charts indicating the 835 frequency of spike:ACE2 inhibiting mAbs for wild type and VOCs

Each experiment was done in triplicates. mGO53 was used as 843 an isotype control. b, Infected area of Vero-TMPRSS2 by wild type

Values were normalized to infected untreated 845 cells. Viral particles were pre-incubated with 100 µg/mL of antibody for 1 h before being added 846 to the cells. Virus infected cells were identified at 24 h post infection using

Statistical 849 analysis was performed using one-way ANOVA and Tukey's multiple comparison test. trimer superimposed on one protomer of the TAU-2212 free spike trimer. Superimpositions of 939 the structures were performed with the S2 portion only. Bottom panel: ribbon diagrams and 940 the long axes of the aligned RBDs showing the TAU-2212 binding induced conformational 941 changes. b, Ribbon diagrams showing that loops

Sequence alignment between the TAU-2212 heavy chain and the human IgG B12 946 heavy chain 67 . The flexible loop "DKTHT" that connects the Fc and Fab of the antibody is 947 highlighted in lime and the cysteines that form a disulfide bond between the loops are 948 highlighted in yellow. b. Ribbon diagram of the crystal structure of human IgG B12, PDB 949 ID:1HZH. Heavy chains are in green and light chains are in salmon. The disulfide bonds are 950 in yellow and the flexible loops are colored lime. c. B12 Fab fitted in the reconstructed maps 951 of conformations 1, 4, 5. The constant and variable regions of the Fab were fitted separately 952 as rigid bodies

Extended Data Fig. 11: Epitopes of antibodies similar to TAU-2212

S2M11 (a) and C144 (b) are shown in yellow. Key mutation sites within or outside the binding 957 epitope of TAU-2303 are colored red and green

Extended Data Table 1: Spike and RBD mutations of the Alpha

Extended Data Table 2: X-ray data collection and refinement statistics for RBD-Fab2303 963 complex and Fab2212

Extended Data Table 3: Contacts between RBD and Fab2303

Extended Data Table 4: Cryo-EM data collection, refinement and validation statistics for RBD-967 Fab2303 and spike-TAU-2212

Extended Data Table 5: Contacts between spike and TAU-2212